NovoCure $NVCR reported EPS of -$0.39, beating the guidance by $0.03. Revenue was $21.7 million, a jump of 141.1%, Y-o-Y, and beating the guidance by $0.6 million. For the nine months ended September 30, 2016, cost of revenue rose to $28.9 million compared to $14.3 million in the corresponding period of last year, representing a 102% growth. Research, development and clinical trials expenses for the nine months ended September 30, 2016 were $33 million, which was nearly flat compared to the same period of 2015.